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Abstract 
 
     A simple meta-analysis of the eight surveys 
of microRNA (miRNA) expression in endometrial 
cancers reveals a panel of sixteen miRNAs that 
are significantly over-expressed (n = 15) or 
under-expressed (n = 1) in at least three 
surveys. Examination of these miRNAs indicates 
that they target mRNAs involved in a number of 
basic cellular processes including the crucial 
epithelial to mesenchymal transition (EMT) and 
hypoxia response. The central role played by 
these miRNAs is reinforced by the 
demonstration that they are all members of 
some of the most ancient of all animal miRNA 
families. This suggests that they may be part of 
a core set of miRNAs dysregulated as part of the 
carcinogenic cellular reprogramming process. 
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Introduction 
 
MicroRNAs (miRNAs) are 22nt long 
non-coding RNAs that, since their initial 
discovery nearly two decades ago, have 
been found to be ubiquitously involved 
in cellular processes throughout the 
plant and animal kingdoms1. MiRNAs 
act to regulate gene expression at both 
the transcriptional and post-
transcriptional level thereby influencing 
hundreds of normal cell functions1. 
Further, dysregulation of miRNAs has 
been shown to play a role in dozens of 
human diseases, including cancers2. 
 
We recently reported on an extensive 
survey of dysregulation of miRNA 
expression in endometrial endometrioid 
adenocarcinomas and endometrial 
serous adenocarcinomas3 and have 
followed that with a just completed 
survey of miRNA dysregulation in 
uterine carcinosarcomas4. Our two 
surveys bring to eight the total number 
of extant studies of miRNA 
dysregulation in endometrial cancers3-10. 
These surveys were carried out on a 
wide range of sample sizes, utilized 
different methodologies, and included a 
spectrum of endometrial cancer types, 
yet the compilation of results presented 
here reveals a core set of sixteen 
miRNAs whose expression was found to 
be significantly dysregulated in three or 
more of the studies. Examination of 
these miRNAs reveals that they affect 
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central cellular processes and are, as a 
group, all members of evolutionarily old 
miRNA families. Thus, these commonly 
dysregulated miRNAs represent the first 
true candidates forming a core panel 
that, with further study, comprise a 
miRNA signature of endometrial cancer 
and, perhaps, other cancers as well. 
 
Table 1. Characteristics of the eight extant miRNA surveys 
Boren et al. (5)    20BE, 37EEA, 4hyperplasia  Hybridization array  335 
   Survey (Ref)        Samples1            Method2          miRNAs3 
Chung et al. (6)    38EEA, 26BE    miR-specific qPCR  157 
Wu et al. (7)     10EEC and NAT   Hybridization array  nd 
Hiroki et al. (8)    21ESA, 7BE    Hybridization array  470 
Ratner et al. (9)    5BE, 11EEA, 6ESA, 6UCS  TLDA (A-set Only)  384 
Cohn et al. (10)    141EEA, number of controls  Hybridization array  326 
       not given 
Devor et al. (3)    4EEA, 4ESA, 4BE   TLDA (A-set and B-set) 667 
Devor et al. (4)    8UCS, 5BE    TLDA (A-set and B-set) 667 
1BE, benign endometrium; EEA, endometrial endometrioid adenocarcinoma; ESA, endometrial serous 
adenocarcinoma; UCS, uterine carcinosarcoma; NAT, normal adjacent tissue 
2Hybridization arrays are from various sources: Invitrogen NCode (Boren et al.), Microarrays Inc. (Wu et 
al.), Agilent (Hiroki et al.), Ohio State University Comprehensive Cancer Center miRNA chip v.3 (Cohn 
et al.) ; miR-specific qPCR primer-probe sets from Life Technologies; TLDA, Life Technologies qPCR-
based Taq-Man Low Density Array (A-set = 384 miRNAs, B-set = 283 miRNAs) 
3Wu et al. do not provide the total number of miRNAs surveyed. 
 
Extant miRNA Surveys of 
Endometrial Cancers 
 
To date, there have been eight surveys 
of miRNA expression in endometrial 
cancers of which seven have been 
published and the eighth is in 
preparation3-10. The general 
characteristics of these miRNA surveys 
are presented in Table 1. As noted, the 
sample sizes and representation of both 
benign endometrium controls and the 
endometrial tumors types vary widely 
from study to study. Further, these 
studies surveyed a varied and only 
partially overlapping minority of the so 
far known total of 1,424 human miRNAs 
(miRBase Release 17, April 2011). 
Whatever the variation in sample size, 
tumor composition, and miRNA 
coverage may be, however, the 
techniques for determining miRNA 
expression levels are limited. In fact, 
there are but two methods available. 
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One, the hybridization array, involves 
fluorescently labeling DNA fragments 
generated by reverse-transcription (RT) 
and hybridizing them to grids spotted 
with synthetic oligonucleotides 
composed of reverse complement (anti-
sense) miRNA sequences. The 
fluorescence intensity of each position in 
the array is then measured and 
analyzed relative to known standards. 
The alternative technology, also based 
upon reverse transcription of cellular 
RNA, involves quantitative PCR (qPCR) 
of RT-generated cDNA fragments using 
primers and fluorescently labeled 
probes (TaqMan assays) specific to 
individual miRNAs. These assays are 
also normalized to endogenous RNA 
standards for subsequent expression 
analyses. 
 
Taken together, the eight miRNA 
surveys overlap by, perhaps, only a few 
dozen miRNAs and yet a panel of 
sixteen miRNAs are found to be 
significantly dysregulated in endometrial 
cancers relative to benign endometrium 
in at least three of the eight surveys 
(Table 2). Moreover, half of these 
sixteen are found to be significantly 
dysregulated in endometrial cancers 
relative to benign endometrium in at 
least four of the eight surveys and two, 
miR-210 and miR-205, are found in six 
of eight and seven of eight surveys 
respectively. 
 
Discussion 
 
MiRNAs function to both preserve the 
overall homeostatic regulation of cellular 
processes and participate in normal 
cellular state transitions. Several 
miRNAs can target the same mRNA 
message and each miRNA can have 
multiple targets. This establishes 
networks of gene regulation involving 
both feed-back and feed-forward loops. 
Thus, when dysregulated, miRNAs can 
potentially be extremely disruptive. In 
cancers, miRNAs have been seen to be 
both significantly over-expressed and 
significantly under-expressed relative to 
benign tissues and to function as tumor 
suppressors or oncogenes depending 
upon the tumor type and tissue of 
origin11,12. However, it is reasonable to 
expect that any particular miRNA will 
function consistently within the same 
cancer type. The sixteen miRNAs 
presented here are not only consistently 
either over- or under-expressed but can 
be expected to be carrying out the same 
pathogenic role in endometrial cancers 
regardless of histologic type. Proof of 
this principle is the presence of the 
entire miR-200 family of miRNAs in 
Table 2. This family, which emerged in 
eumetazoan genomes more than 500 
million years ago13, is composed of five 
miRNAs in two polycistrons, miR-200c 
and miR-141 on chromosome 12 and 
miR-200a, miR-200b and miR-429 on 
chromosome 1. Members of this family 
are well known to be crucially involved 
in epithelial to mesenchymal transition 
(EMT) in uterine and other tissues14 and 
miR-200c has been shown to regulate 
E-cadherin through the transcription 
factors ZEB1 and ZEB215. Coordinately 
regulated with the miR-200 family, miR-
205, the most consistently over-
expressed miRNA in these studies, also 
plays a key role in EMT through 
targeting ZEB1 and SIP116. A miRNA 
study of EMT in uterine 
carcinosarcomas (UCSs) determined 
that expression of miR-200 family 
members are significantly different in the 
epithelial component of UCSs versus 
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the mesenchymal component with the 
former many-fold higher than the 
latter17. Dysregulation of miRNAs 
involved in EMT in endometrial cancers 
is consistent with the central role of EMT 
in both development and cancer18. 
Another miRNA from Table 2 
prominently represented in UCS EMT is 
miR-155, seen to be nearly 80-fold more 
highly expressed in the mesenchymal 
component than in the epithelial 
component17. This miRNA is linked to 
inflammation and has repeatedly been 
observed to be over-expressed in both 
hematologic cancers and solid tumors19. 
 
 
Table 2. microRNAs significantly under- or over-expressed in endometrial cancers compared 
with benign endometrium in three or more of the eight extant surveys of miRNA expression in 
endometrial cancers.  
 
        
Under –expressed: 
microRNA               Number of Studies            References 
 miR-133           4 of  8     [3, 4, 8, 9] 
 
Over-expressed: 
 miR-205  7 of  8     [ 3, 4, 5, 6, 7, 8, 9, 10] 
 miR-210  6 of  8    [3, 4, 5, 6, 7, 8] 
 miR-200a  5 of  8     [3, 6, 7, 8, 9] 
 miR-200c  5 of  8     [3, 6, 7, 8, 10] 
 miR-107  4 of  8     [3, 4, 5, 6] 
 miR-203  4 of  8     [6, 7, 8, 10] 
 miR-182  4 of  8     [6, 7, 8, 9] 
 miR-10a  3 of  8     [6, 7, 8] 
 miR-31  3 of  8     [3, 7, 8] 
 miR-106a  3 of  8     [5, 6, 8] 
 miR-141  3 of  8     [3, 6, 7] 
 miR-155  3 of  8    [3, 6, 7] 
 miR-183  3 of  8     [3, 6, 8] 
 miR-200b  3 of  8     [3, 7, 8] 
 miR-429  3 of  8     [3, 7, 8] 
 
Observed to be significantly over-
expressed in six of the eight miRNA 
surveys, miR-210 offers a very straight-
forward example as well. Numerous 
studies of the relationship between 
hypoxia and miRNA expression have 
shown that miR-210 is the most 
hypoxia-responsive miRNA, intimately 
linked to the hypoxia-inducible factor 
Hif1α20. Moreover, numerous miR-210 
mRNA targets involved in cell cycle 
(PLK1, E2F3) and DNA repair (BLM), 
among others, have been 
experimentally validated. Similarly 
straight-forward is the one miRNA in 
Table 2 that displays significant under-
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expression, miR-133. Another ancient 
miRNA13, miR-133 is actually three 
miRNAs in the human genome; miR-
133a-1 on chromosome 18, miR-133a-2 
on chromosome 20, and miR-133b on 
chromosome 6. The 22nt mature miRNA 
of miR-133a-1 and miR-133a-2 is 
identical and miR-133b differs only in 
position 22 (G→A). Moreover, miR-
133a-1, miR-133a-2, miR-133b are 
polycistronic with miR-1-2/miR-1-1/miR-
206 respectively, which themselves 
share nearly identical mature 
sequences, and this relationship was 
established as long ago as 6.7 x 108 
years ago with the emergence of the 
bilateria. In fact, all
 
 of the miRNAs found 
in Table 2 are members of ancient 
miRNA lineages with most appearing 
well before the emergence of the 
Chordates 5 x 108 years ago (Table 3). 
This is not surprising, since cancer is a 
dramatic re-programming of basic 
cellular functions11 it stands to reason 
that deeply rooted, highly conserved 
miRNAs involved in regulating basic 
cellular functions would be preferentially 
affected.  
Table 3. Evolutionary emergence of the miRNAs in Table 2. Taxon assignments are based upon 
detection of individual miRNAs in representative species reported in Sempere et al.13. 
Eumetazoa             700,000,000  miR-10 
Taxon         Emergence (Years)1           microRNA 
Triploblastica  680,000,000  miR-31 
Nephrozoa  670,000,000  miR-1, miR-133, miR-210 
Deuterostomia  535,000,000  miR-141, miR-183, miR-200 
      miR-429 
Chordata  500,000,000  miR-107 
Osteichthyes  410,000,000  miR-106, miR-155, miR-182 
                                                                        miR-203, miR-205 
1Average of estimates based upon both paleontologic and molecular evidence provided primarily 
in Peterson et al.21. 
 
The miRNA dysregulation signature of 
human endometrial cancer presented 
here, because it is deeply rooted in 
animal evolution, is likely part of a 
generic dysregulation signature in many 
human cancers. Most of these miRNAs 
are seen to be significantly dysregulated 
in other cancers as well including 
leukemia, ovary, lung, prostate, 
colorectal, brain, and pancreas22.   It is 
certainly possible that these 
observations are statistical artifact since 
Proceedings in Obstetrics and Gynecology, 2011 July; 2(1):2 
 
microRNA Signature of Endometrial Cancer   6 
miRNAs with low miRBase archive 
numbers23 are those that were first 
identified and have been included in 
various arrays for several years. On the 
other hand, these miRNAs continue to 
be represented even as the size and 
complexity of miRNA arrays has 
increased. 
 
If there is a functional over-
representation of the more ancient 
miRNAs in human cancers, adding to 
and overlaying this background are 
many miRNAs that appeared following 
the emergence of the land animals13. 
The human miRNAome retains the 
ancient miRNAs but also has hundreds 
of new miRNAs that are only found in 
mammals and more only found in 
primates or in hominids13. When seeking 
to derive a true miRNA signature of 
human endometrial cancers it is 
reasonable to expect that endometrial-
specific miRNA expression patterns will 
be layered over the ancient, generic 
“cancer pattern” presented here. The 
task now is to identify these histology-
specific miRNAs, add them to the core 
miRNAs, and use them to develop 
diagnostic and prognostic assays as 
well as identify their mRNA and pathway 
targets.  
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